Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Merkel Cell Carcinoma: early-phase trial registry
13 of 27 indexed Merkel Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 13 currently recruiting · #598 of 28,707 conditions by registered trial count
Merkel Cell Carcinoma: 27 US clinical trials tracked, 13 recruiting.
Merkel Cell Carcinoma is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 4 of these trials.
Enrollment posture brief
Registry condition merkel-cell-carcinoma
OPEN 13 | RECR 48% | LATE 0 | EARLY 25 | RANK #598 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Intellectual Disability (48% recruiting · 27 trials)
Merkel Cell Carcinoma lists 13 open slots (48% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Merkel Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Merkel Cell Carcinoma is recruiting above its size-band peers.
13 of 27 indexed trials (48.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Merkel Cell Carcinoma trials is spread across many organizations.
H. Lee Moffitt Cancer Center and Research Institute accounts for 4 of 27 trials (14.8%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Merkel Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 27 trials that report a genuine target (sentinel values excluded). 24 of those (88.9%) plan for fewer than 100 participants.
-
Merkel Cell Carcinoma research is mostly interventional.
27 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
NCT02479698
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Ohio State University Comprehensive Cancer Center
NCT06223659
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Replimune
NCT04349436
A Study of CRD3874-SI in People With Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT06021626
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
AstraZeneca
NCT07115043
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center
NCT05859074
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
M.D. Anderson Cancer Center
NCT05100095
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Memgen
NCT05076760
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
AdventHealth Translational Research Institute
NCT06008977
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Weill Medical College of Cornell University
NCT05583708
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Abramson Cancer Center at Penn Medicine
NCT05496036
TIL Therapy in cSCC and MCC
Karam Khaddour, MD, MS
NCT07288073
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
Fujifilm Pharmaceuticals U.S.A.
NCT04047251
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03071406
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04975152
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04869137
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
NCT05358938
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
NCT04792073
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
NCT04616248
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
University of Washington
NCT06056895
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
SOTIO Biotech
NCT05120271
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences
NCT03629756
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Emory University
NCT01526486
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
Claire Verschraegen
NCT03798639
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 12 |
Top Sponsors
Named interventions
Most-linked intervention names on Merkel Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Merkel Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Merkel Cell Carcinoma page
27 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Merkel Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- H. Lee Moffitt Cancer Center and Research Institute sponsors the most Merkel Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See H. Lee Moffitt Cancer Center and Research Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Merkel Cell Carcinoma condition card totals 27 registered trials; most-linked intervention Pembrolizumab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.